|
[1]Nakano T, Lu L, He Y, et al.Population genetic history of hepatitis C virus 1b infection in China[J].J Gen Virol, 2006, 87 (Pt 1) :73-82.
|
|
[2]Kemmer N, Neff GW.Managing chronic hepatitis C in the difficult-to-treat patient[J].Liver Int, 2007, 27 (10) :1297-1310.
|
|
[3]Hughes CA, Shafran SD.Chronic hepatitis C virus management:2000-2005 update[J].Ann Pharmacother, 2006, 40 (1) :74-82.
|
|
[4]Bartosch B, Dubuisson J, Cosset FL.Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes[J].J Exp Med, 2003, 197 (5) :633-642.
|
|
[5]Lindenbach BD, Evans MJ, Syder AJ, et al.Complete replication of hepatitis C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.
|
|
[6]Wakita T, Pietschmann T, Kato T, et al.Production of infectious hepatitis C virus in tissue culture from a cloned viral genome[J].Nat Med, 2005, 11 (7) :791-796.
|
|
[7]Pileri P, Uematsu Y, Campagnoli S, et al.Binding of hepatitis C virus to CD81[J].Science, 1998, 282 (5390) :938-941.
|
|
[8]Grove J, Huby T, Stamataki Z, et al.Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity[J].J Virol, 2007, 81 (7) :3162-3169.
|
|
[9]Kapadia SB, Barth H, Baumert T, et al.Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I[J].J Virol, 2007, 81 (1) :374-383.
|
|
[10]Evans MJ, von HT, Tscherne DM, et al.Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry[J].Nature, 2007, 446 (7137) :801-805.
|
|
[11]Liu S, Yang W, Shen L, et al.Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection[J].J Virol, 2009, 83 (4) :2011-2014.
|
|
[12]Timpe JM, Stamataki Z, Jennings A, et al.Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies[J].Hepatology, 2008, 47 (1) :17-24.
|
|
[13]Pietschmann T.Virology:Final entry key for hepatitis C[J].Nature, 2009, 457 (7231) :797-798.
|
|
[14]Griffin SD, Beales LP, Clarke DS, et al.The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine[J].FEBS Lett, 2003, 535 (1-3) :34-38.
|
|
[15]Pietschmann T, Kaul A, Koutsoudakis G, et al.Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras[J].Proc Natl Acad Sci U S A, 2006, 103 (19) :7408-7413.
|
|
[16]Noppornpanth S, Lien TX, Poovorawan Y, et al.Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus[J].J Virol, 2006, 80 (15) :7569-7577.
|
|
[17]Gosert R, Egger D, Lohmann V, et al.Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons[J].J Virol, 2003, 77 (9) :5487-5492.
|
|
[18]Watashi K, Ishii N, Hijikata M, et al.Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase[J].Mol Cell, 2005, 19 (1) :111-122.
|
|
[19]Li K, Foy E, Ferreon JC, et al.Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF[J].Proc Natl Acad Sci U S A, 2005, 102 (8) :2992-2997.
|
|
[20]Meylan E, Curran J, Hofmann K, et al.Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus[J].Nature, 2005, 437 (7062) :1167-1172.
|
|
[21]Sarrazin C, Rouzier R, Wagner F, et al.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders[J].Gastroenterology, 2007, 132 (4) :1270-1278.
|
|
[22]Inchauspe G, Feinstone S.Development of a hepatitis C virus vaccine[J].Clin Liver Dis, 2003, 7 (1) :243-259.
|
|
[23]Chapel C, Garcia C, Roingeard P, et al.Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles[J].J Gen Virol, 2006, 87 (Pt 4) :861-871.
|
|
[24]Inoue K, Umehara T, Ruegg UT, et al.Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo[J].Hepatology, 2007, 45 (4) :921-928.
|
|
[25]Whitby K, Taylor D, Patel D, et al.Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV:implications for the treatment of hepatitis C[J].Antivir Chem Chemother, 2004, 15 (3) :141-151.
|
DownLoad: